ArticleInflammation2018
Protective Effects of a Rho Kinase Inhibitor on Paraquat-Induced Acute Lung Injuries in Rats.
Article in Inflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 13 citations in OpenAlex.
- Article
- Klotho Alleviates Lung Injury Caused by Paraquat via Suppressing ROS/P38 MAPK-Regulated Inflammatory Responses and Apoptosis.Oxidative medicine and cellular longevity · 2020Article
- Rho and Reactive Oxygen Species at Crossroads of Endothelial Permeability and Inflammation.Antioxidants & redox signaling · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fasudil, a rock kinase inhibitor, can inhibit systemic inflammation and prevent paraquat (PQ)-induced acute lung injuries in rats; however, the mechanisms for these protective effects remain elusive. This study investigated how the Rho/ROCK signaling pathway enables fasudil to protect against acute lung injuries in PQ-treated rats. Wistar rats (n = 240) were pretreated with fasudil (10 and 30 mg/kg, i.p.) 1 h prior to PQ administration. When compared to rats with PQ-induced lung injuries, rats pretreated with fasudil had significantly fewer polymorphonuclear neutrophils and lower concentrations of protein, TNF-α, IL-1β, and IL-6 in their bronchoalveolar lavage fluid. Moreover, fasudil also reduced the Evans Blue content, wet-to-dry weight ratio, lung injury scores, and levels malondialdehyde and 8-hydroxy-2 deoxyguanosine, but increased superoxide dismutase activity in lung tissue. Furthermore, Rho, ROCK1 expression and the levels of phosphorylated MYPT-1 in lung tissues were drastically decreased in fasudil-treated rats, whereas ZO-1 protein expression was significantly increased (p < 0.05). We found that fasudil downregulated bax and activated caspase-3 mRNA expression but upregulated Bcl-2 mRNA expression. In vitro experiments showed that the levels of TNF-α, IL-1β, and IL-6 secreted by human pulmonary microvascular endothelial cells treated with PQ were attenuated by fasudil. Fasudil inhibited the upregulation Rho and ROCK protein expression and downregulation of ZO-1 protein expression in HPMVECs induced with PQ. Higher concentrations of fasudil produced greater affects than lower concentrations. Fasudil improved endothelial permeability and inhibited inflammation, oxidative stress, and cell apoptosis to alleviate acute lung injuries in PQ-treated rats. Fasudil exerted these therapeutic effects by inhibiting the Rho/ROCK signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.